XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.19.3

NOTE 14 – BUSINESS CONCENTRATIONS | 9 Months Ended
--- | ---
Sep. 30, 2019
Risks and Uncertainties [Abstract] |
NOTE 14 – BUSINESS CONCENTRATIONS | NOTE 14 – BUSINESS CONCENTRATIONS We purchase our prescription products from several suppliers with approximately 36%, 28%, and 26% of our purchases supplied by three vendors each, respectively, during the nine months ended September 30, 2019. Approximately 100% of our products were manufactured by one vendor related to each of IMVEXXY and prenatal vitamins during the nine months ended September 30, 2018. We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended September 30, 2019, four customers each generated more than 10% of our total prescription revenues. During the nine months ended September 30, 2018, four customers each generated more than 10% of our total prescription revenues. Prescription revenue generated from the four customers combined accounted for approximately 68% of our prescription revenue for the nine months ended September 30, 2019, and prescription revenue generated from the four customers combined accounted for approximately 71% of our prescription revenue for the nine months ended September 30, 2018. During the nine months ended September 30, 2019, PI Services accounted for approximately $1,935,000 of our prescription revenue, Pillpack, Inc. accounted for approximately $6,397,000 of our prescription revenue, AmerisourceBergen accounted for approximately $2,226,000 of our prescription revenue and Cardinal Health accounted for approximately $1,863,000 of our prescription revenue. During the nine months ended September 30, 2018, PI Services accounted for approximately $1,559,000 of our prescription revenue, Pillpack, Inc. accounted for approximately $3,057,000 of our prescription revenue, AmerisourceBergen accounted for approximately $1,834,000 of our prescription revenue and Cardinal Health accounted for approximately $1,399,000 of our prescription revenue.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration